Aclaris Therapeutics Suffers a Blow from Mixed Results of Eczema Trial
Overview of the Trial Results Aclaris Therapeutics Inc released topline results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (eczema). The trial met the primary efficacy endpoint, the percent change from baseline in the Eczema Area and Severity Index (EASI) score ...












